Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1307 Vaccine Regimen in Muscle-Invasive Bladder Cancer
NCT01094496Phase 2Terminated
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2010
- Primary completion
- Jul 2011
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CDX-1307 in bladder cancer, sponsored by Celldex Therapeutics. Started Apr 2010; status: terminated.
02
Drugs
CDX-1307
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT01094496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094496.